Healthcare Executive Brings Significant Commercial, Operational and Business Development Leadership to the Company
Wilmington, DE and Ashdod, Israel, April 22, 2020 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP), innovator of GlucoTrack®, a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that Yair Briman has joined the Company as a Senior Executive Advisor.
Mr. Briman is a seasoned professional with over 20 years of global leadership experience in the digital healthcare industry. From 2006 through 2019, Mr. Briman served in various senior executive roles at Philips Healthcare, including as Vice President & General Manager, Global Imaging Clinical Applications and most recently as CEO of Philips’ Healthcare Informatics division. In this role he oversaw global informatics operations including HIS (healthcare information systems), EMR (electronic medical records), PACS (picture archiving and communication systems), Advance Visualization, Oncology Informatics, and Cardiology Informatics. During his tenure at Philips, Yair was responsible for sales, marketing and distribution, oversaw the completion and integration of numerous acquisitions, managed global supply chains, and managed over 3,000 employees worldwide. In 2013, Yair Co-founded and served as a board member of Sanara Ventures, a healthcare focused start-up incubator backed by Philips and Teva Pharmaceuticals, where he oversaw investments and supported the creation of 13 healthcare startups. Previously, Mr. Briman served as Vice President of R&D at Gigaspaces and as global manager of software development for Intel.
"We are honored to have Yair as an advisor to Company," said David Malka, President of Integrity. "Yair has a proven track record of building and commercializing healthcare innovation. Having the unique experience of both early stage and global Fortune 500 healthcare companies, his insights will be critical as we continue building GlucoTrack and its digital health platform into a market leader in the management of Type 2 diabetes and prediabetes.”
“I am very excited to work with the Integrity Applications team” said Yair Briman. “In my view, the Type 2 diabetes and prediabetes markets are large, growing and prime for disruption. I look forward to leveraging my experience to help position GlucoTrack into a household name in diabetes and prediabetes care.”
About GlucoTrack®
GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual’s glucose level in about a minute without finger pricking or any pain. GlucoTrack® features an ear clip with sensors that clips to the earlobe and measures the user’s glucose level using innovative and patented sensor technologies. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used to estimate HbA1c level using a proprietary algorithm. The device can also display glucose values graphically, enabling the user to monitor glucose levels over time. GlucoTrack® has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea for type 2 diabetes and prediabetes and is currently available in selected markets in Europe and Asia.
About Integrity Applications, Inc.
Integrity Applications, Inc. (OTCQB: IGAP) was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit http://www.integrity-app.com/ and http://www.glucotrack.com.
Investor Contact: investors@integrity-app.com
Media Contact: media@integrity-app.com
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect”, “plan” and “will” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on April 14, 2020.